Phase II Study of Intratumoral Injection of rF-TRICOMTM in Patients With Metastatic Melanoma Who Have Detectable Tumor Associated T Cells
The Phase II study of rF-TRICOM in patients with metastatic melanoma aims to evaluate the safety and efficacy of intratumoral vaccine therapy. Given the increasing incidence of melanoma and the limited treatment options for advanced stages, this asset has potential commercial value in a competitive landscape dominated by immunotherapies such as checkpoint inhibitors. The trial's focus on patients with detectable tumor-associated T cells may position it favorably in the market, particularly if it demonstrates superior local and systemic responses compared to existing therapies. However, the termination of the study may raise concerns regarding the viability of this approach and necessitate further diligence on the reasons for discontinuation and the implications for future development.
Indication: Recurrent Melanoma
Modality: vaccine
Target: Intratumoral injection of recombinant fowlpox-TRICOM vaccine targeting tumor-associated T cells in metastatic melanoma.
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Intratumoral injection of recombinant fowlpox-TRICOM vaccine targeting tumor-associated T cells in metastatic melanoma.
View original source fields
Condition raw: Recurrent Melanoma, Stage IV Melanoma
Condition normalized: Recurrent Melanoma, Stage IV Melanoma
Modality raw: vaccine
Modality normalized: vaccine
Target raw: Intratumoral injection of recombinant fowlpox-TRICOM vaccine targeting tumor-associated T cells in metastatic melanoma.
Target normalized: Intratumoral injection of recombinant fowlpox-TRICOM vaccine targeting tumor-associated T cells in metastatic melanoma.